Glucagon

Label

ClassPeptide hormone

Typical routes in papersSC/IM/IV / nasal rescue on labels

Half-life contextMinutes

EvidenceFDA-approved rescue; component of dual agonists

What it is

Glucagon tells the liver to dump stored sugar. Emergency kits use it when someone on insulin bottoms out. New obesity duals add a glucagon nudge to raise energy use.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

Approved benefit: rescue severe hypoglycemia.
Metabolic-research benefit (as part of duals): a little more calorie burn and liver-fat talk.
A naked glucagon shot for “fat loss” is nausea and a heart-rate spike, not a protocol.

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

GCGR agonism raises hepatic glucose output, increases energy expenditure, and influences bile-acid / liver-fat pathways at pharmacologic dual-agonist doses.

Possible side effects / caveats

Nausea, tachycardia, rebound high sugar. Pheochromocytoma and insulinoma contraindications on rescue labels.

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Label rescue	1 mg SC/IM/IV (adult typical) or nasal equivalent	Once for severe hypo	Emergency product
Dual-agonist context	See survodutide / mazdutide / pemvidutide		Not standalone fat-loss

Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.